CONMED Corporation enters its July 29 earnings window with a sharp divergence between what options traders are doing now and what they were doing a month ago.
The standout this week is the options market. Put/call positioning has swung dramatically to the bullish side — the ratio dropped to 1.32 on July 10, more than three standard deviations below its 20-day average of 2.12. That 20-day average had been running near two-year highs of around 2.86 in early June, when put demand was heavy. The rotation away from protective puts is sharp enough to be the week's clearest positioning story, and it coincides with a 14% weekly gain in the stock to $38.48.
Short interest tells a steadier, less alarming story. Bears hold around 7% of the free float short — meaningful but not extreme, and it has actually declined roughly 4% over the past month after a brief rebuild this week. The borrow market remains loose: availability runs near 900% of outstanding short interest, meaning shares are plentiful for anyone wanting to add or maintain a position on the short side. Cost to borrow is low at 0.52%, up about 17% on the week but still well within normal territory. The ORTEX short score of 48.2 is mid-range and has barely moved over the past two weeks. Nothing in the lending market suggests a squeeze or forced covering — the week's move looks more like shorts staying put while buyers stepped in.
The Street is not enthusiastic, which makes the price move more interesting rather than less. The consensus is a hold, with no buy ratings among the six covering analysts. BMO Capital initiated coverage on July 9 with a Market Perform and a $36 target — below where the stock now trades. B of A's Travis Steed downgraded to Underperform on June 29, holding a $40 target. The mean price target across the group is $39, essentially flat to current levels. That setup means the 14% weekly rally has taken CNMD above what most analysts think it is worth right now. Forward earnings momentum is a partial offset — the 12-month forward EPS growth estimate ranks in the 72nd percentile of the sector — but near-term EPS surprise history is weak, sitting in the 29th percentile. Bulls can point to BioBrace uptake and Foot & Ankle growth as genuine operational inflection signs; bears point to persistent capital weakness in international markets and a stock that has been in steady decline for the better part of eighteen months.
Institutional ownership gives the bulls some structural support. BlackRock holds 16% of shares and added roughly 50,000 shares through June. Dimensional Fund Advisors added 80,000 shares in the same period. Two Sigma built a position of 2.6% of the company as of March, adding over 500,000 shares. These are methodical accumulators, not momentum buyers, and their continued presence near multi-year lows suggests the valuation case — EV/EBITDA near 6.8x, price-to-book below 1x — is attracting long-only capital even as sell-side sentiment remains cautious.
The next catalytic moment is the July 29 earnings report. Recent prints have produced muted reactions — a 1.9% one-day gain in May, a 0.35% decline in April — so the earnings history does not suggest large binary moves. What makes this setup different is the sharp improvement in options sentiment running into the print, coinciding with a stock that has just reclaimed its analyst mean target from below. Whether the shift in options positioning reflects genuine conviction or short-term positioning ahead of the report is the question worth watching.
See the live data behind this article on ORTEX.
Open CNMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
